Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is 19.11% higher on its value in year-to-date trading and has touched a low of $31.52 and a high of $58.46 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RARE stock was last observed hovering at around $57.79 in the last trading session, with the day’s loss setting it -0.83%.
Currently trading at $56.96, the stock is 8.35% and 22.46% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.52 million and changing -1.44% at the moment leaves the stock 26.51% off its SMA200. RARE registered 55.76% gain for a year compared to 6-month loss of 10.13%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 26.52% gain in the last 1 month and extending the period to 3 months gives it a 47.37%, and is 1.06% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.79% over the week and 4.19% over the month.
Ultragenyx Pharmaceutical Inc. (RARE) has around 1276 employees, a market worth around $5.25B and $481.30M in sales. Profit margin for the company is -121.57%. Distance from 52-week low is 80.71% and -2.57% from its 52-week high. The company has generated returns on investments over the last 12 months (-45.00%).
Ultragenyx Pharmaceutical Inc. quarterly earnings per share for the current quarter are estimated at -1.43 with sales reaching $135.88M over the same period.The EPS is expected to grow by 22.83% this year, but quarterly earnings will post 23.50% year-over-year. Quarterly sales are estimated to grow 38.60% in year-over-year returns.
392.0 institutions hold shares in Ultragenyx Pharmaceutical Inc. (RARE), with institutional investors hold 102.33% of the company’s shares. The shares outstanding are 92.17M, and float is at 86.18M with Short Float at 4.46%. Institutions hold 98.58% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 9.78 million shares valued at $401.98 million. The investor’s holdings represent 11.6039 of the RARE Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.6 million shares valued at $230.3 million to account for 6.648 of the shares outstanding. The other top investors are SANDS CAPITAL MANAGEMENT, LLC which holds 5.35 million shares representing 6.353 and valued at over $220.08 million, while WELLINGTON MANAGEMENT GROUP LLP holds 5.4056 of the shares totaling 4.56 million with a market value of $187.26 million.
Ultragenyx Pharmaceutical Inc. (RARE) Insider Activity
The most recent transaction is an insider sale by KAKKIS EMIL D, the company’s President & CEO. SEC filings show that KAKKIS EMIL D sold 20,000 shares of the company’s common stock on Aug 06 ’24 at a price of $50.17 per share for a total of $1.0 million. Following the sale, the insider now owns 2.24 million shares.
Still, SEC filings show that on Jul 02 ’24, Sanders Corazon (Corsee) D. (Director) disposed off 584 shares at an average price of $40.98 for $23932.0. The insider now directly holds 12,009 shares of Ultragenyx Pharmaceutical Inc. (RARE).
